Author:
Yacobi Avraham,Shah Vinod P.,Bashaw Edward D.,Benfeldt Eva,Davit Barbara,Ganes Derek,Ghosh Tapash,Kanfer Isadore,Kasting Gerald B.,Katz Lindsey,Lionberger Robert,Lu Guang Wei,Maibach Howard I.,Pershing Lynn K.,Rackley Russell J.,Raw Andre,Shukla Chinmay G.,Thakker Kailas,Wagner Nathalie,Zovko Elizabeta,Lane Majella E.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference44 articles.
1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products—general considerations.2003.
2. Code of Federal Regulations. Title 21 Part 320 0.24 (b) (1–4)
3. www.regulations.gov/#!documentDetail;D=FDA-2012-P-0779-0004
4. Abbreviated New Drug Application 202459.
5. Guidance: topical dermatologic corticosteroids: in vivo bioequivalence, Office of Generic Drugs, Center for Drug Evaluations and Research, FDA. 1995.
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献